Gilead Connecticut, Inc.

Incarda Therapeutics, Inc.

United Therapeutics Corporation

Michael Laird Hurrey

Luiz Belardinelli

Dimitrios Stefanidis

Carlos A Schuler

Dragos Vizitiu

Peter Chee-Chu Fung

Tim G Elford

Prashanti Madhavapeddi

Drazen Ostovic

Peter Noymer

This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.

Enhanced solubility drug-containing formulations

Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.

Antiarrhythmic formulation

Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.

Polymorph of Syk inhibitors

Growing community of inventors

San Ramon, CA, United States of America

Michael Laird Hurrey